Menu
8:00 ET
Welcome
Raymond Kim, MD, PhD, FRCPC, FACMG
Medical Geneticist, Associate Professor, University of Toronto, Ontario, Canada
8:15 ET
Keynote Address: VHL: Gene to Pathway to Precision Management to Therapy
W. Marston Linehan, MD
Chief of Urologic Surgery and the Urologic Oncology Branch, Center for Cancer Research, at the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
9:15 ET
Break
9:30 ET
Natural history and treatment of Hemangioblastomas in VHL patients:
The MGH experience
Othon Iliopoulos, MD, PhD
Clinical Director, von Hippel-Lindau Disease/Familial Renal Cell Cancer Program, Massachusetts General Hospital Cancer Center, Boston, MA, USAAssociate Professor of Medicine, Harvard Medical School, Boston, MA, USA
10:00 ET
Investigating PIkfyve and Lysosomes as Target in VHL Disease
Sandra Turcotte, PhD
Canadian Cancer Society Research Chair, Canada Researcher in Residency, Atlantic Cancer Research Institute, CanadaAssociate Professor, Department of Chemistry and Biochemistry, New Brunswick Centre for Precision Medicine, Canada
10:30 ET
Proffered Abstract: Tumor heterogeneity analysis using single-cell transcriptomics in Von Hippel-Lindau related renal cancer
10:45 ET
Break
11:00 ET
The Quest after the Oncogenic Drivers for VHL-Related Pancreatic Neuroendocrine Tumors
Amit Tirosh, MD
Associate Professor of Medicine, Aviv University Faculty of Medicine, Tel Aviv, Israel
Director, ENTIRE Translational Research Center for Endocrine Cancer, Sheba Medical Center, Israel
11:30 ET
Psychosocial Impact of VHL – New Insights and Challenges
Rachel van Leeuwaarde, MD, PhD
Department of Endocrine Oncology, University Medical Center Utrecht, the Netherlands
12:00 ET
Jess
12:30 ET
Lunch Break
1:00 ET
Nontraditional Tumor Associated Antigens in ccRCC
William Y. Kim, MD
Rush S. Dickson Professor of Medicine, Genetics, and Pharmacology,
Division of Oncology Co-leader Cancer Genetics Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA
1:30 ET
VHL and Other Emergent Pseudohypoxic Diseases: Lessons from pVHL/HIF2a and PHD2/HIF2a Crystal Structures
Fraser Ferens, PhD
Post-Doctoral Fellow, Ohh Laboratory, University of Toronto, Toronto, Canada
2:00 ET
VHL-Independent Heterogeneity of Hypoxia Signaling in Renal Cell Carcinomas
Hamed S. Najafabadi, PhD
Canada Research Chair, Systems Biology of Gene RegulationAssistant Professor, Department of Human Genetics, McGill University, Canada
2:30 ET
Closing Remarks
Othon Iliopoulos, MD, PhD, VHLA Board Member
Stephen Parrott, CVHLA Board Chair
2:45 ET
Break
3:00 ET
Poster Session
3:30 ET
Poster Session
4:00 ET
Poster Session
7:55 ET
Welcome
Raymond Kim, MD, PhD, FRCPC, FACMG
Medical Geneticist, Associate Professor, University of Toronto, Ontario, Canada
8:00 ET
Eric Jonasch, MD
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Texas, USA
8:30 ET
Tumor Surveillance for Children and Adolescents with Cancer Predisposition Syndromes: The Psychosocial Impact Reported by Adolescents and Caregivers
Kalene van Engelen, MSc, CGC, CCGC
Certified Genetic Counsellor, London Health Sciences Centre, London, Ontario, Canada
9:00 ET
Andrew Gowan
9:30 ET
Prashant Chittiboina, MD
National Institutes of Health, Maryland, USA10:00 ET
Breaking News in Pheochromocytoma and Paraganglioma Surgery
Martin K. Walz, MD
Head and Professor of Surgery, Kliniken Essen-Mitte Academic Hospital of the University of Duisburg-Essen, Cologne Bonne Region, Germany
10:30 ET
Updates on the Journey of Testing Treatments of Ocular Hemangioblastomas Associated with VHL
Emily Chew, MD
Senior Investigator, Division of Epidemiology and Clinical Applications, Clinical Trials Branch, National Institute of Health, Bethesda, MD, USA
11:00 ET
Sarah Ridd
Department of Medicine, Division of Medical Oncology, University Health Network, Toronto, Ontario, Canada11:15 ET
Break
11:30 ET
Poster Session
12:00 ET
12:30 ET
VHL Tumor Board
2:30 ET
Closing Remarks
Joshua Mann, MPH, VHLA Director of Health
Patty Milburn, CVHLA Secretary
7:55 ET
Welcome
Raymond Kim, MD, PhD, FRCPC, FACMG
Medical Geneticist, Associate Professor, University of Toronto, Ontario, Canada
8:00 ET
Hypoxia-Inducible Factors Mediate Immune Evasion of Cancer Cells
Gregg L. Semenza, MD, PhD
VHL Foundational Speaker Professor, Genetic Medicine, Pediatrics, Radiation Oncology, and Molecular Radiation Sciences, Biological Chemistry, Medicine, and Oncology, Johns Hopkins University School of Medicine
2019 Nobel Prize Recipient, Physiology or Medicine
8:30 ET
VHL and Oxygenases – Not Just Degradation?
Christopher J. Schofield, PhD
Department Head and Professor, Organic Chemistry, Department of Chemistry, University of Oxford, Oxford, England
Fellow of the Royal Society, England
9:00 ET
Patricia Dahia, PhD
Professor of Medicine, University of Texas Health Science Center at San Antonio, Texas, USA
9:15 ET
Break
9:30 ET
Paul Nathan, MD, MSc
Head, Solid Tumor Section Director, Aftercare Program, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, CanadaProfessor, Departments of Paediatrics and Healthy Policy, Management & Evaluation, University of Toronto, Toronto, Canada
10:00 ET
Patient Corner
Jane Beasley
10:25 ET
Reut Halperin, MD, PhD
Senior Clinical Associate, VHL Clinical Care Center, Division of Endocrinology, Diabetes and Metabolism and ENTIRE -Endocrine Neoplasia Translational Research Center, Sheba Medical Center, IsraelSenior Physician, Faculty of Medicine, Tel Aviv University, Israel
10:40 ET
Ozgur Mete, MD, FRCPC
Professor, University of Toronto Department of Laboratory Medicine & Pathobiology – Anatomic Pathology, Canada
11:00 ET
Management of VHL-Associated Pheochromocytoma or Pancreatic Lesions Including Pancreatic Neuroendocrine Tumors
Electron Kebebew, MD, FACS
Professor of Surgery, Harry A. Oberhelman, Jr. and Mark L. Welton Professor, Stanford University School of Medicine, California, USA Chief, Division of General Surgery, Stanford Medicine, California, USA11:30 ET
Update on Hereditary Pheochromocytoma
Karel Pacak, MD, PhD, DSc, FACE Senior Investigator, Division of Intramural Research, National Institute of Health, Bethesda, MD, USA
12:00 ET
Jennifer Galenkamp, VHLA Board Member
Stephen Parrott, CVHLA Board Chair
12:15 ET
12:30 ET
2022© VHL Symposium